Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. boosted its stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 13.6% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,134,276 shares of the company's stock after acquiring an additional 136,087 shares during the period. Charles Schwab Investment Management Inc. owned 0.82% of Vir Biotechnology worth $8,496,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in VIR. Intech Investment Management LLC acquired a new position in Vir Biotechnology in the 3rd quarter valued at $191,000. Quest Partners LLC increased its stake in shares of Vir Biotechnology by 171.4% during the third quarter. Quest Partners LLC now owns 34,455 shares of the company's stock worth $258,000 after acquiring an additional 21,760 shares during the period. Victory Capital Management Inc. increased its position in Vir Biotechnology by 23.9% during the 3rd quarter. Victory Capital Management Inc. now owns 81,269 shares of the company's stock worth $609,000 after purchasing an additional 15,696 shares during the period. China Universal Asset Management Co. Ltd. increased its position in Vir Biotechnology by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 26,280 shares of the company's stock worth $197,000 after purchasing an additional 10,294 shares during the period. Finally, Blue Trust Inc. grew its holdings in Vir Biotechnology by 143.5% during the third quarter. Blue Trust Inc. now owns 3,989 shares of the company's stock worth $30,000 after acquiring an additional 2,351 shares during the period. 65.32% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Needham & Company LLC reaffirmed a "buy" rating and set a $19.00 price objective on shares of Vir Biotechnology in a report on Wednesday, November 20th. Barclays lowered their target price on shares of Vir Biotechnology from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Monday, November 4th. Finally, HC Wainwright restated a "buy" rating and set a $110.00 target price on shares of Vir Biotechnology in a research report on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $36.40.

Vir Biotechnology Stock Performance

NASDAQ VIR traded down $0.27 during trading hours on Wednesday, reaching $7.82. The company's stock had a trading volume of 696,999 shares, compared to its average volume of 1,069,417. The stock has a market cap of $1.08 billion, a PE ratio of -2.06 and a beta of 0.49. Vir Biotechnology, Inc. has a fifty-two week low of $6.56 and a fifty-two week high of $13.09. The company's 50-day moving average is $8.03 and its two-hundred day moving average is $8.69.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The company reported ($1.56) EPS for the quarter, missing the consensus estimate of ($1.05) by ($0.51). The business had revenue of $2.38 million during the quarter, compared to analyst estimates of $5.54 million. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The firm's revenue for the quarter was down 9.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.22) earnings per share. Equities analysts expect that Vir Biotechnology, Inc. will post -3.36 earnings per share for the current fiscal year.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).